Search

Displaying results 3021 - 3030 of 10000 in total
  1. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51103,L51108] It has also been available in Japan since 2020 under the brand name Ecclock.[L51103] … [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.

  2. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. … It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

  3. Drug

    SGS-742

    go.drugbank.com/drugs/DB05010
    Investigational

    SGS-742 has been used in trials studying the treatment of Seizures and Metabolic Disease.

    Synonyms: (3-Aminopropyl)(n-butyl)phosphinic acidCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    on anti-PD-1 therapy. … on a PD-1-blocking antibody-based regimen.

  5. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    Gadopiclenol is a gadolinium-based contrast agent (GBCA) based on a pyclen macrocyclic structure. … [A254002,A254017] In September 2022, the use of gadopiclenol was approved by the FDA.

  6. Drug

    Viral Macrophage-Inflammatory Protein

    go.drugbank.com/drugs/DB15748
    Experimental

    Viral macrophage inflammatory protein-II (vMIP) is a highly basic protein and human chemokine analog encoded by human herpesvirus-8. The structure of vMIP consists of 71 residues and is a monomer under most conditions. It helps its virus...

  7. Drug

    Ponesimod

    go.drugbank.com/drugs/DB12016
    ApprovedInvestigational

    Ponesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]

  8. Drug

    Bromodiphenhydramine

    go.drugbank.com/drugs/DB01237
    Approved

    Bromodiphenhydramine is an ethanolamine antihistamine with antimicrobial property. Bromodiphenhydramine is used in the control of cutaneous allergies. … Ethanolamine antihistamines produce marked sedation in most patients.

    Synonyms: 2-(p-bromo-α-phenylbenzyloxy)-N,N-dimethylethylamine
  9. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

  10. Drug

    L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

    go.drugbank.com/drugs/DB06124
    Experimental

    C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal